SynaptiCOM.net is composed of three 'translational technology' initiatives.
Our specific aims include:
1) noticeably advancing rural population health strategies, and
2) developing next-generation minimally-invasive nano-transponder technology (U.S. Patents 8,788,033, 9,302,114, and 9,802,050).
Our novel nanotechnology remains on track for augmenting neuromodulation therapies for stabilizing medically-resistant epilepsies and co-occurring mental health conditions. Together our aims strive to maximize 'effective connectivity from synapse to community'.
Our translational laboratory brain mapping initiative is evolving a suite of innovative human brain mapping techniques for visualizing the 'footprint' of epileptogenic brain circuits. These neurovisualization software packages are, in turn, supporting the 'nanotech R&D' initiative. We are developing a nano-sized technology for potential use with brain modulation therapy strategies. Both our innovative brain mapping platforms and nanotechnology will facilitate establishing a new market and value network for effectively impacting medically-resistant epilepsy.
The core of our populaton health implementation initiative includes a CARF-accredited rural mobile health (mHealth) outreach platform embedded within the Epilepsy Foundation of North Central Illinois. The initiative was founded prior to the U.S. Affordable Care Act and now energized by it. Our platform is designed to deliver cutting-edge specialized healthcare. The ultimate application of this mHealth-rich initiative will coordinate and maintain optimal healthcare patterns for individuals living in rural communities throughout the U.S. This aim defines population health management (PHM).
The majority of these communities in which 60 million residents live, are located geographically distant from large regional medical centers. The mHealth initiative is coordinated by a dedicated 'community-based' PHM hub equipped with a unique scalable rural electronic health record portal.
Our PHM initiative collaborates with regional tertiary medical centers, predominantly RUSH University Medical Center in Chicago, IL. `
All three SynaptiCOM.net translational technology initiatives are energized by ongoing collaborative partners and sponsors. These include industry, academic institutions, rural community service organizations, county, state and federal grant resources, private foundations, and valued philanthropy.
The founder of SynaptiCOM.net, Marvin A. Rossi, MD, PhD, is a board-certified neurologist and epileptologist with a doctorate in Molecular Biophysics. Dr. Rossi has 30 years of translational research experience within regional NAEC-affiliated specialized epilepsy centers (predominantly the RUSH Epilepsy Center).